Exploiting PRMT5 as a target for combination therapy in mantle cell lymphoma characterized by frequent ATM and TP53 mutations

Constant challenges for the treatment of mantle cell lymphoma (MCL) remain to be recurrent relapses and therapy resistance, especially in patients harboring somatic mutations in the tumor suppressors ATM and TP53, which are accumulated as therapy resistance emerges and the disease progresses, consis...

Descripción completa

Detalles Bibliográficos
Autores principales: Che, Yuxuan, Liu, Yang, Yao, Yixin, Hill, Holly A., Li, Yijing, Cai, Qingsong, Yan, Fangfang, Jain, Preetesh, Wang, Wei, Rui, Lixin, Wang, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9935633/
https://www.ncbi.nlm.nih.gov/pubmed/36797243
http://dx.doi.org/10.1038/s41408-023-00799-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9935633/
https://www.ncbi.nlm.nih.gov/pubmed/36797243
http://dx.doi.org/10.1038/s41408-023-00799-6

Ejemplares similares